Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.02B P/E - EPS this Y 47.90% Ern Qtrly Grth -
Income -292.12M Forward P/E -15.92 EPS next Y 39.10% 50D Avg Chg -10.00%
Sales 1.36B PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 7.65 EPS next 5Y - 52W High Chg -26.00%
Recommedations 1.70 Quick Ratio 3.89 Shares Outstanding 123.68M 52W Low Chg 29.00%
Insider Own 3.70% ROA -14.18% Shares Float 119.14M Beta 1.53
Inst Own 98.67% ROE -40.78% Shares Shorted/Prior 7.58M/7.62M Price 43.93
Gross Margin 53.85% Profit Margin -21.47% Avg. Volume 977,151 Target Price 130.83
Oper. Margin -10.62% Earnings Date Nov 6 Volume 880,597 Change -3.15%
About Natera, Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc. News
11/15/24 Natera, Inc. (NASDAQ:NTRA) Just Reported And Analysts Have Been Lifting Their Price Targets
11/14/24 Stanley Druckenmiller's Strategic Emphasis on Natera Inc in Q3 2024
11/14/24 Natera Third Quarter 2024 Earnings: Beats Expectations
11/13/24 Natera Stock Explodes 20% After Record-Breaking Q3--Is This Biotech Giant Just Getting Started?
11/13/24 Natera Inc (NTRA) Q3 2024 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ...
11/13/24 Decoding Natera Inc (NTRA): A Strategic SWOT Insight
11/12/24 Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11/12/24 Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
11/12/24 Natera: Q3 Earnings Snapshot
11/12/24 Natera Reports Third Quarter 2024 Financial Results
11/12/24 Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
11/08/24 Natera to Participate in Upcoming Investor Conferences
11/01/24 Natera to Report its Third Quarter 2024 Results on November 12, 2024
10/30/24 Exploring Three High Growth Tech Stocks in the United States
10/30/24 Loss-Making Natera, Inc. (NASDAQ:NTRA) Expected To Breakeven In The Medium-Term
10/23/24 All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy
10/22/24 Natera to Present New Renasight Data at ASN Kidney Week 2024
10/06/24 Natera Inc. (NTRA): Hedge Funds Are Bullish On This NASDAQ Stock Right Now
09/30/24 High Growth Tech Stocks To Watch In September 2024
09/24/24 Natera, Inc. (NASDAQ:NTRA) Shares Could Be 23% Above Their Intrinsic Value Estimate
NTRA Chatroom

User Image kh286 Posted - 13 hours ago

$NTRA what happened AH?

User Image TradetheChanges Posted - 19 hours ago

$NTRA this is one of those stocks that you want to just hold and enjoy the ride

User Image mavsmoneyline Posted - 21 hours ago

$NTRA avg in

User Image jeffmeredith Posted - 21 hours ago

$NTRA Heading for another ath

User Image IN0V8 Posted - 1 day ago

$NTRA Opportunity UBS raises target price to $209 from $145

User Image danelfin Posted - 1 day ago

$NTRA chart since Jun 2024. Green dots are past AI-powered BUY signals. In the 3M forecast, the central dotted line is the most expected price path (+19.28%). The shaded area (-19.92% to +58.40%) is the expected price range based on prev. BUY signals (90% confidence level). Suggested $NTRA trading parameters (3M horizon): entry $153, stop loss $132, take profit $218.58.

User Image danelfin Posted - 1 day ago

How sharp were our AI-powered ratings for $NTRA in the past? Danelfin's 453 past BUY signals for $NTRA since Jan. 2017 achieved average positive performance, alpha, and win rate across various investing time frames. Not indicative of future results. https://danelfin.com/stock/NTRA#track-record

User Image danelfin Posted - 1 day ago

For our #AI, $NTRA is a BUY (AI Score 9/10) based on the probability of beating the market in 3 months after analyzing 10,000 fundamental, technical, and sentiment stock features. Complete AI-powered $NTRA analysis: https://danelfin.com/stock/NTRA

User Image danelfin Posted - 1 day ago

$NTRA chart since Jun 2024. Green dots are past AI-powered BUY signals. In the 3M forecast, the central dotted line is the most expected price path (+19.28%). The shaded area (-19.92% to +58.40%) is the expected price range based on prev. BUY signals (90% confidence level). Suggested $NTRA trading parameters (3M horizon): entry $153, stop loss $132, take profit $218.58.

User Image danelfin Posted - 1 day ago

For our #AI, $NTRA is a BUY (AI Score 9/10) based on the probability of beating the market in 3 months after analyzing 10,000 fundamental, technical, and sentiment stock features. Complete AI-powered $NTRA analysis: https://danelfin.com/stock/NTRA

User Image swingingtech Posted - 2 days ago

$NTRA https://wallstreetwaves.com/options-trading-insights-for-natera-ntra-in-early-july-2025/

User Image erevnon Posted - 2 days ago

Piper Sandler maintains Natera $NTRA at Overweight and raises the price target from $150 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image MaverikIT Posted - 2 days ago

@IsabellaDC @net0trader @DonCorleone77 Isabella $EAT ing well and paying with $FOUR and speaking da language$ $DUOL - another 52wk$ $NTRA

User Image MaverikIT Posted - 2 days ago

@IsabellaDC @net0trader $NTRA +7.07 - after breather

User Image FolikoInvest Posted - 2 days ago

$NTRA Natera's recent Q3 results have sparked excitement, showcasing a narrower loss and impressive sales of $439.8 million, exceeding expectations. With a bullish 2024 revenue forecast that outstrips market estimates, can Natera maintain this momentum in a competitive healthcare landscape? https://folikoinsights.com/article/NTRA/2024/11/18/natera-surges-22-3-after-reporting-strong-q3-results-and-optimistic-2024-revenue-forecast-prompting?cid=cb0g9BBkFERsXODd

User Image FolikoInvest Posted - 3 days ago

$NTRA Natera's recent Q3 results have sparked excitement, showcasing a narrower loss and impressive sales of $439.8 million, exceeding expectations. With a bullish 2024 revenue forecast that outstrips market estimates, can Natera maintain this momentum in a competitive healthcare landscape? https://folikoinsights.com/article/NTRA/2024/11/17/natera-surges-22-3-after-reporting-strong-q3-results-and-optimistic-2024-revenue-forecast-prompting?cid=tJWOsQQW0No2QrTQ

User Image Doozio Posted - 6 days ago

$NTRA shocking it was by far Drucks largest pos last qtr! N he added to $dakt which he is the 3rd largest holder n it has yet to have an eps gap n go INTA 🧠⏰♾️

User Image Cutlass Posted - 6 days ago

$NTRA Out for now, solid run ✔

User Image phatsuit Posted - 6 days ago

Keep it going mothafuckers!!! $NTRA

User Image IN0V8 Posted - 6 days ago

$NTRA Morgan Stanley raises target price to $176.00 from $132.00

User Image seekingthebest Posted - 1 week ago

$NTRA 185$ double top breakout

User Image Cutlass Posted - 1 week ago

$NTRA Trimmed 👌🤠

User Image jParkz Posted - 1 week ago

News out $NTRA Natera Inc. (NASDAQ: NTRA) is a Leading Gainer in Wednesday Morning Trading https://marketwirenews.com/news-releases/natera-inc-nasdaq-ntra-is-a-leading-gainer-in-wednes-7505332485983824.html $NTRA

User Image erevnon Posted - 1 week ago

Craig-Hallum maintains Natera $NTRA at Buy and raises the price target from $121 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image homer212 Posted - 1 week ago

$NTRA still here and rich

User Image SM07 Posted - 1 week ago

$NTRA Price has reached a point where it is now totally disjointed from value.

User Image MaverikIT Posted - 1 week ago

@Stocktwits $NTRA $SEZL

User Image Stocktwits Posted - 1 week ago

$NTRA is up 245% this past year and only has 1,863 watchers 👀

User Image jeffmeredith Posted - 1 week ago

$NTRA $167.43 ath, wish I owned more of this

User Image MaverikIT Posted - 1 week ago

@IsabellaDC @net0trader $SEZL - da smell$$$$ of burning shorts they may need $NTRA to diagnose ...

Analyst Ratings
Piper Sandler Overweight Sep 13, 24
Canaccord Genuity Buy Aug 27, 24
Morgan Stanley Overweight Aug 13, 24
Piper Sandler Overweight Aug 13, 24
TD Cowen Buy Aug 9, 24
BTIG Buy Aug 9, 24
Stephens & Co. Overweight Aug 9, 24
UBS Buy Aug 9, 24
Baird Outperform Aug 9, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Feb 01 Sell 67.7295 22,281 1,509,081 70,646 02/02/24
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 26 Sell 65.09 3,235 210,566 92,927 01/30/24
Sheena Jonathan - - Jan 26 Sell 65.09 546 35,539 478,585 01/30/24
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Jan 26 Sell 65.09 4,265 277,609 204,218 01/30/24
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Jan 26 Sell 65.09 14,813 964,178 246,957 01/30/24
Moshkevich Solomon PRESIDENT, CLINICALD.. PRESIDENT, CLINICALDIAGNOSTICS Jan 29 Sell 65.09 3,426 222,998 194,977 01/30/24
Fesko John PRESIDENT, CHIEF BUS.. PRESIDENT, CHIEF BUS. OFFICER Jan 26 Sell 65.09 2,358 153,482 108,494 01/30/24
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 24 Sell 67 944 63,248 64,810 01/26/24
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 20 Sell 66.89 2,973 198,864 65,754 01/23/24
Sheena Jonathan - - Jan 20 Sell 68.16 351 23,924 469,726 01/23/24
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Jan 20 Sell 68.16 1,958 133,457 175,550 01/23/24
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Jan 20 Sell 68.16 892 60,799 181,050 01/23/24
Sheena Jonathan - - Jan 03 Sell 60.48 6,000 362,880 21,155 01/05/24
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Dec 27 Sell 62.79 2,292 143,915 64,810 12/29/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Dec 27 Sell 63.29 2,604 164,807 172,348 12/29/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Sep 23 Sell 45.2972 1,674 75,828 71,438 12/29/23
Sheena Jonathan - - Dec 27 Sell 62.4 1,447 90,293 21,655 12/29/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Dec 27 Sell 63.29 728 46,075 180,442 12/29/23
Marcus Gail Boxer Director Director Dec 08 Sell 57.52 500 28,760 20,146 12/12/23
Sheena Jonathan - - Dec 06 Sell 58.52 5,000 292,600 474,743 12/08/23
Chapman Rowan E Director Director Nov 29 Sell 55.9714 1,998 111,831 9,373 12/01/23
Marcus Gail Boxer Director Director Nov 21 Sell 54.3136 1,000 54,314 20,646 11/22/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Nov 20 Sell 55 2,566 141,130 217,554 11/22/23
Sheena Jonathan - - Nov 02 Sell 40.31 6,000 241,860 22,155 11/03/23
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Oct 20 Sell 40.55 3,940 159,767 64,810 10/24/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Oct 20 Sell 40.39 2,595 104,812 220,120 10/24/23
Sheena Jonathan - - Oct 20 Sell 40.14 1,335 53,587 22,655 10/24/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Oct 20 Sell 40.39 803 32,433 179,807 10/24/23
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Sep 27 Sell 45.9 2,291 105,157 64,833 09/29/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Sep 27 Sell 45.82 2,617 119,911 217,554 09/29/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Sep 27 Sell 45.82 732 33,540 179,110 09/29/23
Sheena Jonathan - - Sep 27 Sell 45.94 5,448 250,281 484,745 09/29/23
Sheena Jonathan - - Sep 06 Sell 59.26 6,000 355,560 23,155 09/08/23
Sheena Jonathan - - Sep 01 Sell 60.0062 10,000 600,062 494,746 09/01/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Aug 11 Sell 55 2,578 141,790 214,988 08/14/23
Sheena Jonathan - - Aug 02 Sell 44.17 6,000 265,020 504,746 08/04/23
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jul 25 Sell 46.58 2,347 109,323 64,833 07/27/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Jul 20 Sell 47.83 800 38,264 178,478 07/24/23
Sheena Jonathan - - Jul 20 Sell 47.63 1,333 63,491 509,746 07/24/23
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jul 20 Sell 47.83 1,570 75,093 67,180 07/24/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Jul 20 Sell 47.83 2,578 123,306 217,566 07/24/23
Brophy Michael Burkes CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Apr 25 Sell 50.99 4,656 237,409 64,833 06/29/23
Chapman Steven Leonard CEO AND PRESIDENT CEO AND PRESIDENT Jun 27 Sell 50.88 2,605 132,542 214,983 06/29/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Jun 27 Sell 50.88 728 37,041 177,778 06/29/23
Sheena Jonathan - - Jun 27 Sell 50.85 5,447 276,980 509,746 06/29/23
Chapman Rowan E Director Director Jun 13 Sell 50.5750 1,767 89,366 8,621 06/15/23
Sheena Jonathan - - Jun 07 Sell 48.93 6,000 293,580 24,655 06/09/23
Sheena Jonathan - - May 10 Sell 54.11 5,000 270,550 519,746 05/12/23
Sheena Jonathan - - Apr 20 Sell 54.49 333 18,145 524,746 04/24/23
RABINOWITZ DANIEL SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER Apr 20 Sell 54.63 796 43,485 177,143 04/24/23